IP Library › Granted Patent US 7,588,908
Granted Patent B2
US 7,588,908 · App. 10/338,182 · Granted Sep 15, 2009

Compositions and methods for inhibiting light-induced inactivation of biological reagents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,588,908
App. No.
10/338,182
Granted
Sep 15, 2009
Kind
B2
Abstract

Disclosed is a fluorescent conjugate comprising a biological reagent, a fluorescent molecule, and a means for impeding phototoxic degradation of the biological reagent. The impeding means can be a cross-linking substance having a long molecular distance, whereby the cross-linking substance links the fluorescent molecule and the biological reagent; a quencher of singlet oxygen; a quencher of a free radical; or a combination thereof. Also disclosed is a solution comprising a fluorescent conjugate of a biological reagent and a fluorescent molecule together with an oxygen depleting system.

Claims (21)

1. A fluorescent composition for use in an assay for an analyte of interest, comprising:

a particle;

one or more fluorescent molecules bound to the surface of or within said particle;

a biological reagent selected from the group consisting of a receptor for said analyte of interest and a ligand analogue that competes with said analyte of interest for binding to a receptor, said biological reagent directly or indirectly bound to said particle, wherein said biological reagent is selected from the group consisting of an antibody, a nucleic acid, a protein, and a peptide; and

one or more protective agents comprising an antioxidant within said particle, said protective agent(s) configured and arranged to protect said biological reagent from inactivation when said particle is exposed to light and oxygen.

2. A fluorescent composition according to claim 1 , wherein said particle is a latex particle.

3. A fluorescent composition according to claim 1 , wherein said particle is a liposorne.

4. A fluorescent composition according to claim 1 , wherein said particle is an alumina particle.

5. A fluorescent composition according to claim 1 , wherein said particle is a silica particle.

6. A fluorescent composition according to claim 1 , wherein said particle comprises one or more fluorescent molecules within said particle.

7. A fluorescent composition according to claim 6 , wherein said protective agent(s) comprise a protein adsorbed to the surface of said particle.

8. A fluorescent composition according to claim 7 , wherein said biological reagent is indirectly bound to said particle through said protein.

9. A fluorescent composition according to claim 1 , wherein said biological reagent is directly bound to said particle.

10. A fluorescent composition according to claim 1 , wherein said antioxidant is selected from the group consisting of lycopene, lutein, β-carotene, bixin, corcetin, physalien, nickel complex, stilbene, and BHA.

11. A fluorescent composition according to claim 1 , wherein said protective agent(s) comprise a protein adsorbed to the surface of said particle.

12. A fluorescent composition according to claim 11 , wherein said biological reagent is indirectly bound to said particle through said protein.

13. A fluorescent composition according to claim 6 , wherein said protective agent(s) comprise a heterofunctional crosslinking reagent between said biological reagent and said particle, said heterofunctional crosslinking reagent having a length sufficient to protect said biological reagent from inactivation when said particle is exposed to light and oxygen.

14. A fluorescent composition according to claim 13 , wherein said heterofunctional crosslinking reagent is selected from the group consisting of succinimidyl-4-(N-maleirnidomethyl)-cyclohexane-1-carboxy-(6-amido-caproate) and succinimidyl-6-[3-(2-pyridyldithio)propionarnido]hexanoate.

15. A fluorescent composition according to claim 1 , wherein said fluorescent composition is suspended in an aqueous solvent.

16. A fluorescent composition according to claim 15 , wherein said aqueous solvent comprises an antioxidant.

17. A fluorescent composition according to claim 15 , wherein said aqueous solvent comprises an oxygen depleting system.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CARDIOVASCULAR INC.
Reel/Frame 060052/0786 →
TRIAGE ASSIGNMENT, ASSUMPTION AND BILL OF SALE Recorded Oct 24, 2017
From: ALERE SAN DIEGO, INC.
To: QUIDEL CARDIOVASCULAR INC.
Reel/Frame 044281/0152 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 043803/0359 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →